Dr Shlomit Halachmi
MD, PhD, Consultant Dermatologist, Israel
Employment
Current:
Dec 2007- Attending dermatologist, Rabin Medical Center, Department of Dermatology – Laser Unit Petach Tikva, Israel
July 2008- Dermatologist in private practice, Herzelia Dermatology and Laser Center Herzelia Pituach, Israel
2001-2004 and Feb 2007 Dermatologist, Department of Dermatology, Harvard University, Holyoke Center, Cambridge, MA USA
Prior:
2005-2007 UltraShape Ltd., Israel
2006-2007 VP Medical Affairs
2005 Director of Future Applications
2004-2005 BioLineRx Ltd., Israel
2005 Director of Medical Marketing
2004 Project Manager, Drug Development
Education and Training
2000 - 2001 Academic Chief Resident, Combined Dermatology Program
Boston University / Tufts - New England Medical Center, Boston, MA USA
1998 - 2001 Resident, Combined Dermatology Program
Boston University / Tufts - New England Medical Center, Boston, MA USA
1997 - 1998 Medical Intern, Department of Internal Medicine
Beth Israel Hospital, Harvard Medical School, Boston, MA USA
1991 - 1997 M.D.- Ph.D. Program
Harvard Medical School, Boston, MA USA
Ph.D. Division of Cellular and Developmental Biology and Dana-Farber Cancer
Institute: “Characterization and Cloning of an Estrogen Receptor Coactivator”
M.D. Division of Health Sciences and Technology (HST), Harvard Medical School and
Massachusetts Institute of Technology.
1987 - 1991 Massachusetts Institute of Technology, Cambridge, MA USA
B.S. Chemical Engineering
B.S. Biology
Minor concentration, 19th Century British Literature
Board Certification and Licensing
USA:
1998 Massachusetts Board of Registration in Medicine; license active and in good standing
2001 Board Certification - American Board of Dermatology; active and in good standing
Israel:
2005 Medical license; active and in good standing
2008 Specialty license in Dermatology
Research Experience
1991 - 1997 Doctoral thesis in the laboratory of Myles Brown, M.D., Harvard Medical School
and Dana-Farber Cancer Institute, Boston, MA USA
Identified first steroid receptor coactivators and corepressors (Science, 1994; Nature 1995), and cloned cDNA
for a novel transcriptional modulator (Mol. Cell. Biol, 2002). These are now known as the class of histone
modulators (HDAC’s and HAT’s)
1989 - 1991 Laboratory of Robert Weinberg, Ph.D., Massachusetts Institute of Technology
and Whitehead Institute for Biomedical Research, Cambridge, MA USA
Knockout mouse models of p53, Rb (Current Biology, 1994)
1988 - 1989 Laboratory of Stanley Cohen, Ph.D., Department of Biochemistry, Vanderbilt
University, Nashville, TN USA
Production of recombinant prepro-EGF
1987 - 1988 Laboratory of Robert Langer, Ph.D., Department of Chemical Engineering,
Massachusetts Institute of Technology, Cambridge, MA USA
Controlled release in drug delivery via microencapsulated liposomal system
Fellowships
1993 - 1996 Howard Hughes Medical Institute Predoctoral Fellow
Awards
2001 Dermatology Foundation Dermatology Investigator Research Fellowship awardee
2000 Ligand Pharmaceuticals Young Investigator Award
1993, 1995 American Association for Cancer Research Young Investigator Award
1993 Richard A. Smith Award, Dana-Farber Cancer Institute
1989, 1990 Burchard Scholar, Massachusetts Institute of Technology
Patents
“Novel salts of conjugated psychotropic drugs and processes of preparing same” WO/2006/131923
Other Certifications
2008 Good Clinical Practice (GCP) certification, Association of Clinical Research Professionals (ACRP)
Citizenship
United States
Israel
Languages
English
Hebrew
Publications
Halachmi S and Lapidoth M. Combined laser / optical and radiofrequency treatment of the face. 2009.
Kosmetische Medizin, 8: 134-141.
Halachmi S and Lapidoth M. Lasers in skin cancer prophylaxis. 2008. Expert Rev Anticancer Ther.
8(11): 1713-7.
Pavlovsky L, Mimouni D, Halachmi S, David M. Pemphigus mimicking as common skin diseases –
atypical presentation delaying correct diagnosis: case series of five patients. 2008. Isr Med Assoc J.
10: 433-434.
Halachmi S, Yaar M, and Gilchrest BA. Advances in skin aging/photoaging: theoretical and practical
implications. 2005. Ann Dermatol Venereol. 132(4): 362-7.
Curiel-Lewandrowski C and Halachmi S. Risk factors for the development of melanoma. In: UpToDate, Rose, BD
(Ed), UpToDate, Wellesley, MA, 2003. (www.uptodate.com)
Halachmi S. “Clinical Update: Gout.” Dermatology, Continuing Medical Education. Medscape.com
August 2003.
Shao W, Halachmi S, and Brown M. ERAP140, a conserved tissue-specific nuclear receptor coactivator. 2002.
Mol. Cell. Biol. 22(10): 3358-72.
Halachmi S and Gilchrest BA. Update on genetic events in the pathogenesis of melanoma. 2001. Current
Opinion in Oncology 13(2): 129-136.
Demierre M and Halachmi S. Mycosis Fungoides in the Workplace. In: Elgart ML, Ed. Clinics in Occupational
and Environmental Medicine: Occupational Dermatology. Vol. 1. Philadelphia, Penn.: W.B. Saunders, 2001:
107-132.
Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown, M. p300 is a component of
an estrogen receptor coactivator complex. 1996. Proc. Natl. Acad. Sci. USA 93: 11540-11545.
Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK. Polarity-specific activities
of retinoic acid receptors determined by a co-repressor. 1995. Nature 377: 451-454.
Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins:
possible mediators of hormone-induced transcription. 1994. Science 264: 1455-1448.
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum
analysis in p53-mutant mice. 1994. Current Biology 4:1-7.
